1Grimer RJ. Surgical options for children with osteosarcoma [J]. Lancet Oneol, 2005, 6(2):85-92.
2Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols[J]. J Clin Oncol, 2002, 20(3):776-790.
3Marina N, Gebhardt M, Teot L, et al. BioLogy and therapeutic advances for pediatric osteosarcoma[J]. Oncologist, 2004, 9(4):422-441.
4Bacci G, Loro L, Longhi A, et al. No correlation between methotrexate serum level and histologic response in the pre-operative treatment of extremity osteosarcoma[J]. Anticancer Drugs, 2006, 17(4):411-415.
5Zelcer S, Kellick M, Wexler LH, et al. Methotrexate levels and outcome in osteosarcoma [J]. Pediatr Blood Cancer, 2005, 44(7):638-642.
6Eselgrim M, Grunert H, Kuhne T, et al. Dose intensity of chemotherapy for osteosarcoma and outcome in the Cooperative Osteosarcoma Study Group (COSS) trials[J]. Pediatr Blood Cancer, 2006, 47(1):42-50.
7Crews KR, Liu T, Rodriguez-Galindo C, et al. High dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma[J]. Cancer, 2004, 100 (8):1724-1733.
8Isobe K, Shimizu T, Nikaido T, et al. Low-voltage electrochemotherapy with low-dose methotrexate enhances survival in mice with osteosarcoma[J]. Clin Orthop Relat Res, 2004, (426) :226-231.
9Bacci G,Briccoli A,Ferrari S,et al. Neoadjuvant chemotherapy for osteosarcoma of the extremity: long-term results of the Rizzoli's 4th protocol[J]. Eur J Cancer, 2001, 37(16): 2030-2039.
10Le Deley MC, Guinebretiere JM, Gentet GC, et al. SFOP OS94. A randomised trial comparing preoperative highdose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients[J}. Europ J Cancer, 2007, 43(4):752-761.
